Kura Oncology, Inc.
DE ˙ DB ˙ US50127T1097
7,56 € ↑0,24 (3,28%)
2026-06-05
DEL PRIS
SecurityDE:KUR / Kura Oncology, Inc.
InstitutionProShare Advisors LLC
Latest Disclosed Ownership15,582 shares
Latest Disclosed Value $ 126,681
ProShare Advisors LLC reports 16.10% decrease in ownership of KUR / Kura Oncology, Inc.

On April 24, 2026 - ProShare Advisors LLC filed a 13F-HR form disclosing ownership of 15,582 shares of Kura Oncology, Inc. (DE:KUR) valued at $103,620 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 6, 2026 disclosing 18,572 shares of Kura Oncology, Inc.. This represents a change in shares of -16.10% during the quarter. The current value of the position is $117,800 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-24 2026-03-31 13F KURA ONCOLOGY COM 50127T109 15,582 -2,990 -16.10 127 -34.37 0.0002
2026-02-06 2025-12-31 13F KURA ONCOLOGY COM 50127T109 18,572 1,692 10.02 193 28.86 0.0003
2025-11-06 2025-09-30 13F KURA ONCOLOGY COM 50127T109 16,880 -2,569 -13.21 149 33.04 0.0003
2025-08-07 2025-06-30 13F KURA ONCOLOGY COM 50127T109 19,449 -216 -1.10 112 -13.18 0.0002
2025-05-08 2025-03-31 13F KURA ONCOLOGY COM 50127T109 19,665 -4,438 -18.41 130 -38.28 0.0003
2025-02-14 2024-12-31 13F KURA ONCOLOGY COM 50127T109 24,103 5,873 32.22 210 -41.29 0.0005
2024-11-14 2024-09-30 13F KURA ONCOLOGY COM 50127T109 18,230 4,075 28.79 356 22.34 0.0009
2024-08-13 2024-06-30 13F KURA ONCOLOGY COM 50127T109 14,155 -3,859 -21.42 291 -24.22 0.0008
2024-05-08 2024-03-31 13F KURA ONCOLOGY COM 50127T109 18,014 1,588 9.67 384 62.71 0.0010
2024-02-14 2023-12-31 13F KURA ONCOLOGY COM 50127T109 16,426 2,407 17.17 236 85.83 0.0007
2023-11-13 2023-09-30 13F KURA ONCOLOGY COM 50127T109 14,019 1,114 8.63 128 -6.62 0.0004
2023-08-10 2023-06-30 13F KURA ONCOLOGY COM 50127T109 12,905 510 4.11 137 -9.93 0.0004
2023-05-26 2023-03-31 13F/A-1 KURA ONCOLOGY COM 50127T109 12,395 -1,614 -11.52 152 -12.72 0.0005
2023-05-12 2023-03-31 13F KURA ONCOLOGY COM 50127T109 12,395 -1,614 152 0.0005
2023-02-02 2022-12-31 13F KURA ONCOLOGY COM 50127T109 14,009 1,388 11.00 174 0.00 0.0006
2022-11-07 2022-09-30 13F KURA ONCOLOGY COM 50127T109 12,621 303 2.46 173 -23.45 0.0007
2022-08-01 2022-06-30 13F KURA ONCOLOGY COM 50127T109 12,318 -6,491 -34.51 226 -25.17 0.0007
2022-05-10 2022-03-31 13F KURA ONCOLOGY COM 50127T109 18,809 -4,423 -19.04 302 -7.08 0.0006
2022-02-08 2021-12-31 13F KURA ONCOLOGY COM 50127T109 23,232 928 4.16 325 -22.25 0.0006
2021-11-12 2021-09-30 13F KURA ONCOLOGY COM 50127T109 22,304 -6,089 -21.45 418 -29.39 0.0012
2021-08-13 2021-06-30 13F KURA ONCOLOGY COM 50127T109 28,393 2,510 9.70 592 -19.13 0.0017
2021-05-14 2021-03-31 13F KURA ONCOLOGY COM 50127T109 25,883 3,503 15.65 732 0.14 0.0023
2021-02-09 2020-12-31 13F KURA ONCOLOGY COM 50127T109 22,380 6,806 43.70 731 53.25 0.0027
2020-11-13 2020-09-30 13F KURA ONCOLOGY COM 50127T109 15,574 -348 -2.19 477 83.46 0.0022
2020-08-03 2020-06-30 13F KURA ONCOLOGY COM 50127T109 15,922 15,922 260 0.0014
2020-05-15 2020-03-31 13F KURA ONCOLOGY COM 50127T109 0 -14,451 -100.00 0 -100.00
2020-02-12 2019-12-31 13F KURA ONCOLOGY COM 50127T109 14,451 -1,696 -10.50 199 -18.78 0.0009
2019-11-12 2019-09-30 13F KURA ONCOLOGY COM 50127T109 16,147 2,005 14.18 245 -11.87 0.0014
2019-08-13 2019-06-30 13F KURA ONCOLOGY COM 50127T109 14,142 -1,854 -11.59 278 4.91 0.0017
2019-05-15 2019-03-31 13F KURA ONCOLOGY COM 50127T109 15,996 123 0.77 265 18.83 0.0016
2019-02-14 2018-12-31 13F KURA ONCOLOGY COM 50127T109 15,873 -3,076 -16.23 223 -32.83 0.0016
2018-11-14 2018-09-30 13F KURA ONCOLOGY COM 50127T109 18,949 1,661 9.61 332 5.40 0.0023
2018-08-13 2018-06-30 13F KURA ONCOLOGY COM 50127T109 17,288 568 3.40 315 0.32 0.0021
2018-05-14 2018-03-31 13F KURA ONCOLOGY COM 50127T109 16,720 -2,550 -13.23 314 6.44 0.0020
2018-02-14 2017-12-31 13F KURA ONCOLOGY COM 50127T109 19,270 19,270 295 0.0020
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.